Wellness
Sexism is a risk factor for memory decline among women

Women born in the most sexist U.S. states experience faster memory decline in later years compared to women born in the least sexist states, according to a new study.
The difference between being born in the most versus the least sexist state was equivalent to nine years of cognitive ageing.
The study is one of a growing number of studies that have investigated links between structural sexism and health.
Structural sexism, like structural racism, does not refer to personal incidences but to inequality in resources and power that stem from social policies and societal norms. Hate crimes or slurs are individual acts of racism or sexism; unfair lending practices and underrepresentation in government are structural.
Previous studies have found that exposure to greater structural sexism in adulthood is associated with higher mortality rates, increased risk of chronic health conditions, and less accessible and affordable health care for women.
The study calculated each state’s level of structural sexism during the decades the women were born based on male-to-female ratios in the labour force, the number of females in state legislatures, poverty rates, and other factors.
The researchers then looked at relationships between structural sexism levels and memory performance among 21,000 people in the Washington Heights-Inwood Columbia Aging Project and the Health and Retirement Study.
The study also found that the association between structural sexism and memory performance was highest among Black women.
“It is likely that, for women racialised as Black, the intersectional impact of sexism and racism creates a unique form of oppression that has greater salience for cognitive health than sexism or racism alone,” says Jennifer Manly, professor of neuropsychology, senior author of the study.
“Our findings suggest that addressing social inequities may be a powerful way to lower the burden of Alzheimer’s among women,” said study leader Justina Avila-Rieger, an associate research scientist in the Gertrude H. Sergievsky Center Columbia.
“Alzheimer’s is a huge societal problem, particularly among women, who account for two-thirds of Americans with the disease. It’s imperative that we gain a better understanding of what is causing this discrepancy and what can be done about it.”
Studies of why Alzheimer’s disease affects women more than men have largely focused on sex-linked biological differences, such as hormones and genes. The new study suggests that one of the most important and underappreciated risk factors may be systemic sex and gender discrimination.
How structural sexism contributes to memory decline is not clear.
“What we do know is structural inequalities shape individual health outcomes by creating barriers to health-enhancing opportunities and resources,” said Avila-Rieger.
“Eventually, these exposures produce disparities in chronic physical health conditions that directly influence brain health, the onset of cognitive impairment and, ultimately, dementia.”
In future studies, Avila-Reiger plans to look at the effects of exposure to structural sexism at different stages of life.
“It’s possible that early life exposure may be a critical period for structural inequality, with direct or indirect consequences that accumulate over time,” she said.
“We also need to tease apart which aspects of structural sexism have the most impact on cognitive health. This is important in terms of making recommendations to policy makers.”
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.













